ORBIMED ADVISORS LLC 13D and 13G filings for Enliven Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-05-20 4:55 pm Sale | 2024-05-16 | 13D | Enliven Therapeutics, Inc. ELVN | ORBIMED ADVISORS LLC | 7,918,163 16.800% | -1,033,300 (-11.54%) | Filing |
| 2024-04-04 4:39 pm Purchase | 2024-04-02 | 13D | Enliven Therapeutics, Inc. ELVN | ORBIMED ADVISORS LLC | 8,951,463 19.200% | 2,124 (+0.02%) | Filing |
| 2023-02-28 4:00 pm Purchase | 2023-02-23 | 13D | Enliven Therapeutics, Inc. ELVN | ORBIMED ADVISORS LLC | 8,949,339 21.800% | 8,949,339 (New Position) | Filing |